カニクイザルのブレオマイシン肺線維症モデル
【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of pulmonary function. Although many bleomycin-induced pulmonary fibrosis has been studied as IPF model in rodent, IPF model in nonhuman primates has...
Saved in:
Published in | 日本薬理学会年会要旨集 p. 1-P-123 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | Japanese |
Published |
公益社団法人 日本薬理学会
2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | 【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of pulmonary function. Although many bleomycin-induced pulmonary fibrosis has been studied as IPF model in rodent, IPF model in nonhuman primates has not been reported. In this study, we investigate a cynomolgus monkey model of bleomycin-induced pulmonary fibrosis by IPF related biomarker and pathology. 【Methods】Two cynomolgus monkeys were injected transtrachealy with bleomycin (2mg/kg) once a week for the first 2 weeks. The blood and bronchoalveolar lavage fluid (BALF) were collected at 0, 1, 4, 7, 9, 14, 21, 28 days after the first bleomycin injection, and cytokine levels were measured. On day 29, lung hydroxyproline content was measured. The formalin fixed lungs were stained with HE or Masson's trichrome for microscopic observation. 【Result and Discussion】 After bleomycin injection, BALF IL-1β levels were significantly increased on day 1 and returned almost normal level on day 4. The BALF MCP-1 levels were gradually increased and reached peak from day 4 to day 9. The BALF TGF-beta1 levels reached the maximum on days 7 or 9. The serum TGF-beta1 levels showed almost the same tendency as the BALF levels. The lung hydroxyproline contents of bleomycin injected monkeys were increased about 1.4 times more than normal. Histological examination showed a significant interstitial fibrosis with destruction of the alveolar architecture and was similar to IPF of human. This study provided new model using nonhuman primate for drug development in IPF. |
---|---|
AbstractList | 【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of pulmonary function. Although many bleomycin-induced pulmonary fibrosis has been studied as IPF model in rodent, IPF model in nonhuman primates has not been reported. In this study, we investigate a cynomolgus monkey model of bleomycin-induced pulmonary fibrosis by IPF related biomarker and pathology. 【Methods】Two cynomolgus monkeys were injected transtrachealy with bleomycin (2mg/kg) once a week for the first 2 weeks. The blood and bronchoalveolar lavage fluid (BALF) were collected at 0, 1, 4, 7, 9, 14, 21, 28 days after the first bleomycin injection, and cytokine levels were measured. On day 29, lung hydroxyproline content was measured. The formalin fixed lungs were stained with HE or Masson's trichrome for microscopic observation. 【Result and Discussion】 After bleomycin injection, BALF IL-1β levels were significantly increased on day 1 and returned almost normal level on day 4. The BALF MCP-1 levels were gradually increased and reached peak from day 4 to day 9. The BALF TGF-beta1 levels reached the maximum on days 7 or 9. The serum TGF-beta1 levels showed almost the same tendency as the BALF levels. The lung hydroxyproline contents of bleomycin injected monkeys were increased about 1.4 times more than normal. Histological examination showed a significant interstitial fibrosis with destruction of the alveolar architecture and was similar to IPF of human. This study provided new model using nonhuman primate for drug development in IPF. |
Author | 山之内, 智彦 櫻庭, 峻 館田, 智昭 岡林, 佐知 光岡, ちほみ 安田, 仁 佐々木, 麻衣 山崎, 則之 北島, 俊一 |
Author_xml | – sequence: 1 fullname: 岡林, 佐知 organization: (株)新薬リサーチセンター – sequence: 2 fullname: 櫻庭, 峻 organization: (株)新薬リサーチセンター – sequence: 3 fullname: 安田, 仁 organization: (株)新薬リサーチセンター – sequence: 4 fullname: 山之内, 智彦 organization: (株)新薬リサーチセンター – sequence: 5 fullname: 佐々木, 麻衣 organization: (株)新薬リサーチセンター – sequence: 6 fullname: 光岡, ちほみ organization: (株)新薬リサーチセンター – sequence: 7 fullname: 山崎, 則之 organization: (株)新薬リサーチセンター – sequence: 8 fullname: 館田, 智昭 organization: (株)新薬リサーチセンター – sequence: 9 fullname: 北島, 俊一 organization: (株)新薬リサーチセンター |
BookMark | eNo9j7tKA0EYhQdRMMY8go-wcS47mZlKJBgVAqbQevj3pruscdmNhaU7hYV9BAsLsTJeCiEBX-cv4mMYr8134HA48K2R5eHZMCZkg9E249LfzIqqOi-KvG1Em1rmDTzGxRJpcF9IzzdSrJJWVaUB9VlHdqTUDbKF9QTdNdavWD9gPUU3wcsXdGN0T1g_orv77mfo3j7q9_nsdj59nt9cobtHt-BknawkkFdx6zeb5Ki3c9jd8_oHu_vd7b6XcUGpBxL82AgRRDqgTFPFFWUyApBS8Y4yKgm5NkoHcWKCiIYqCXygEQUNkRYqEk3S-_nNqhEcx7Yo01MoLyyUozTMY_unbo2w9AvMDuzC_n8QnkBpMxCfLiBwXw |
ContentType | Journal Article |
Copyright | 2020 本論文著者 |
Copyright_xml | – notice: 2020 本論文著者 |
DOI | 10.1254/jpssuppl.93.0_1-P-123 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2435-4953 |
ExternalDocumentID | article_jpssuppl_93_0_93_1_P_123_article_char_ja |
GroupedDBID | ALMA_UNASSIGNED_HOLDINGS M~E |
ID | FETCH-LOGICAL-j2300-a5a4e933bd8b0180727015daa55726797fc28978bef9bd0c7fb4a0d0a8ad837d3 |
IngestDate | Wed Apr 05 02:30:27 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Japanese |
LinkModel | OpenURL |
MeetingName | 日本薬理学会年会要旨集 第93回日本薬理学会年会 |
MergedId | FETCHMERGED-LOGICAL-j2300-a5a4e933bd8b0180727015daa55726797fc28978bef9bd0c7fb4a0d0a8ad837d3 |
Notes | 93_1-P-123 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/jpssuppl/93/0/93_1-P-123/_article/-char/ja |
ParticipantIDs | jstage_primary_article_jpssuppl_93_0_93_1_P_123_article_char_ja |
PublicationCentury | 2000 |
PublicationDate | 2020 |
PublicationDateYYYYMMDD | 2020-01-01 |
PublicationDate_xml | – year: 2020 text: 2020 |
PublicationDecade | 2020 |
PublicationTitle | 日本薬理学会年会要旨集 |
PublicationYear | 2020 |
Publisher | 公益社団法人 日本薬理学会 |
Publisher_xml | – name: 公益社団法人 日本薬理学会 |
SSID | ssib041656558 ssib044754519 ssib041654217 |
Score | 1.824586 |
Snippet | 【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of... |
SourceID | jstage |
SourceType | Publisher |
StartPage | 1-P-123 |
SubjectTerms | lung |
Title | カニクイザルのブレオマイシン肺線維症モデル |
URI | https://www.jstage.jst.go.jp/article/jpssuppl/93/0/93_1-P-123/_article/-char/ja |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | 日本薬理学会年会要旨集, 2020, pp.1-P-123 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR09b9UwMCplYUEgQHyrA55QHnESx_ZUxa95qhhQh1bqFsUvyfCGUqF2YUAiGRjYQWJgQEw8PgakVuJP8CM8PH4Gd87HC7QDLVJkXc7nu_OdE99FtuM4D7IioEE5LdxQl6ELb0nmSggb3Cxkmkea-rS0C2SfRJs74eNdtrty4edg1dLhgR5Nn5-6r-Q8XgUc-BV3yZ7Bsz1TQAAM_oUSPAzlP_mYJAERPomVBeBSHWbSAWELqKilaYkpiZMWI_uqcdcq7qqSE3x4W6UCkgiLAWKOeNkAEYk3EJCciI449jsNe4wahsUkiZA-ZhYYW00EKoYAsPKIACUZco4BCIkaW3GMKElUOMAIJIDetQwFSSSRioj-A6RtBB1qSBKkglFmOWygIBQ3AU2W9BHaTCnbMEYVLD1DCyg1ZAsWFdIyAGZezxak0z-kU7ywRlqPMeycYA096CStSRnqE0fDrzK-1z9BthXrzAMSrO3BSyrBKsDEATIDHSWzsmK4Hp7Pzs0kbmcLH-JeFxcLD2Yj6m65tNnOfWKm9FmIM-U-PN2Q7oxkMIJscEn_1yHk7RBPO_pUBqmHBU23UmiSdgS4VzCdQcJy0eeQeuNa2hdJ94IPceucv8yn8T4anDeHh0_icUftTjtQ8dGpCkK0OIPcqVt3aUPB7SvO5TaHW4sbZa46K7PsmrNuqrmpX5vqm6k-murI1HPz8qup35j6s6k-mfq9xR-b-vuv6sfi-N3i6Mvi7StTfzA1lPPrzs4k2R5vuu3fSdwZpO2em7EsLGQQ6FxoPAUPEgEIrfMsY4z7EZe8nPpCcqGLUurcm_JSh5mXe5nIchHwPLjhrO493StuOmu8lGGkJdUSZkeGP3gofa2nGdUwtCjlt5z1pr_pfnMETXpWf9z-bw53nEs4zpuvj3ed1YNnh8U9iMcP9H3r499kP7Fa |
link.rule.ids | 315,786,790,4043,27956,27957,27958 |
linkProvider | ISSN International Centre |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%82%AB%E3%83%8B%E3%82%AF%E3%82%A4%E3%82%B6%E3%83%AB%E3%81%AE%E3%83%96%E3%83%AC%E3%82%AA%E3%83%9E%E3%82%A4%E3%82%B7%E3%83%B3%E8%82%BA%E7%B7%9A%E7%B6%AD%E7%97%87%E3%83%A2%E3%83%87%E3%83%AB&rft.jtitle=%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A%E5%B9%B4%E4%BC%9A%E8%A6%81%E6%97%A8%E9%9B%86&rft.au=%E5%B2%A1%E6%9E%97%2C+%E4%BD%90%E7%9F%A5&rft.au=%E6%AB%BB%E5%BA%AD%2C+%E5%B3%BB&rft.au=%E5%AE%89%E7%94%B0%2C+%E4%BB%81&rft.au=%E5%B1%B1%E4%B9%8B%E5%86%85%2C+%E6%99%BA%E5%BD%A6&rft.date=2020&rft.pub=%E5%85%AC%E7%9B%8A%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A&rft.eissn=2435-4953&rft.spage=1-P-123&rft_id=info:doi/10.1254%2Fjpssuppl.93.0_1-P-123&rft.externalDocID=article_jpssuppl_93_0_93_1_P_123_article_char_ja |